보고서 요약(국문)

시장 개요
글로벌 항비만 약물 시장은 2022년 25억 달러 규모에 도달했으며, 2023년부터 2030년까지 연평균 45.5%의 성장률을 보이며 2030년에는 437억 달러에 이를 것으로 예상됩니다.
비만은 체내에 과도한 지방이 축적되어 건강에 해로운 영향을 미칠 수 있는 질환입니다. 일반적으로 체질량지수(BMI)가 30 이상인 경우로 정의됩니다. 비만은 선진국과 개발도상국 모두에서 가장 크고 빠르게 증가하는 공중 보건 문제로 인식되고 있습니다. 항비만 약물은 비만 환자를 돕기 위해 처방되는 의약품입니다. 이러한 약물은 식욕 억제, 신진대사 촉진 또는 음식물로부터 지방 흡수 차단 등의 방식으로 작용합니다.
이 시장은 비만 인구 증가, 인식 개선 및 신제품 출시로 인해 성장하고 있습니다. 신약 개발을 위한 연구 활동과 시장 참여자 간의 합병, 확장, 인수 및 협력을 포함한 시장 개발이 수요 증가를 견인하고 있습니다.

시장 동향
비만 인구 증가가 항비만 약물 시장 성장을 견인
비만 인구 증가는 예측 기간 동안 전 세계 항비만 약물 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어, 세계비만연맹(World Obesity Federation)이 발표한 2022년 세계 비만 아틀라스(World Obesity Atlas 2022)에 따르면, 2030년까지 전 세계적으로 10억 명 이상(여성 5명 중 1명, 남성 7명 중 1명 포함)이 비만으로 살아갈 것으로 예상됩니다.
또한, 2022년 3월 세계보건기구(WHO)는 전 세계적으로 10억 명 이상이 과체중이며, 이 중 6억 5천만 명이 성인, 3억 4천만 명이 청소년, 3천9백만 명이 어린이라고 발표했습니다. 마찬가지로, WHO는 2025년까지 약 1억 6천7백만 명이 과체중 또는 비만으로 인해 건강이 악화될 것으로 예측했습니다.

2023년 3월, 세계비만연맹(WOF)은 2035년까지 전 세계 인구의 절반에 해당하는 40억 명 이상이 비만이 될 것으로 예상된다는 보고서를 발표했습니다. 또한, 세계비만연맹이 발표한 '2023년 세계 비만 아틀라스'에 따르면, 비만 예방 및 치료 기준이 개선되지 않을 경우 과체중 및 비만으로 인한 다국적 경제적 손실은 2035년까지 연간 4조 3200억 달러에 이를 것으로 예상됩니다.
비만 치료제 연구 활동 증가로 인해 향후 몇 년 동안 전 세계 비만 치료제 시장에 성장 기회가 창출될 것으로 예상됩니다.
비만 치료제 연구 활동이 증가함에 따라 전 세계 비만 치료제 시장은 향후 몇 년 동안 유망한 성장 기회를 맞이할 것으로 예상됩니다. 예를 들어, 2022년 6월, 항비만 약물 개발에 주력하는 임상 단계 바이오제약 회사인 이노벤트 바이오로직스(쑤저우) 유한회사는 중국에서 진행한 비만 치료용 글루카곤 유사 펩타이드 1 수용체(GLP-1R) 및 글루카곤 수용체(GCGR) 이중 작용제인 IBI362의 2상 임상 시험(NCT04904913)의 주요 결과를 발표했습니다.
높은 약물 비용이 예측 기간 동안 전 세계 항비만 약물 시장 성장을 저해할 것으로 예상됩니다.
항비만 약물의 높은 비용은 예측 기간 동안 전 세계 항비만 약물 시장 성장을 저해할 것으로 예상됩니다. 예를 들어, 웨고비(Wegovy) 4주 치료 과정의 월평균 비용은 1,349달러이며, 약물 보험 적용 대상자는 더 적은 금액을 지불합니다. 또한, 체중 재증가를 방지하기 위해 평생 약물 복용을 유지해야 한다는 점을 고려해야 합니다.

이 보고서에 대한 자세한 내용은 샘플을 요청하세요.
세그먼트 분석
세계 항비만 약물 시장은 작용 기전, 약물 유형, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
전문의약품 유형이 세계 항비만 약물 시장을 주도할 것으로 예상됩니다.
전문의약품 유형은 여러 규제 기관의 제품 승인 증가로 인해 세계 시장 점유율의 약 57.8%를 차지할 것으로 예상됩니다. 예를 들어, 2021년 11월 노보 노디스크는 유럽 의약품청(EMA) 산하 인체용 의약품 위원회(CHMP)가 비만 성인의 만성 체중 관리를 위한 웨고비(Wegovy)의 상업화 허가를 긍정적으로 평가했다고 발표했습니다.

또한, 2022년 6월 미국 식품의약국(FDA)은 큐시미아(Qsymia)를 12세 이상 과체중 소아 환자의 체중 유지를 위한 추가 적응증으로 승인했습니다. 여기서 과체중이란 연령 및 성별을 기준으로 표준화된 체질량지수(BMI)가 상위 95% 이상인 경우를 말합니다. 큐시미아는 저칼로리 식단 및 강도 높은 운동과 병행하는 것이 권장됩니다.
지리적 시장 침투
북미 지역은 비만 인구 증가로 인해 2030년까지 전 세계 시장 점유율의 약 38.3%를 차지할 것으로 예상됩니다.
북미 지역의 비만 인구 증가로 인해 2030년까지 전 세계 시장의 약 38.3%를 점유하며 시장을 주도할 것으로 전망됩니다. 예를 들어, 미국 건강 신탁(TFAH)의 제19차 미국 비만 현황 보고서인 "2022년 비만 현황 - 더 건강한 미국을 위한 더 나은 정책"에 따르면 미국 성인 10명 중 4명이 비만이며, 전국적으로 비만율은 계속 증가하고 있습니다.
또한, 미국 질병통제예방센터(CDC)의 고도 비만 프로그램(HOP 2023)에 따르면, 잘못된 식습관과 부족한 신체 활동은 전반적인 건강에 악영향을 미치며 비만 및 만성 질환으로 이어지는 주요 위험 요인입니다. 미국에서는 성인 1억 10만 명(41.9%)과 아동 1,470만 명(19.7%)이 비만으로 고통받고 있으며, 이로 인해 연간 약 1,470억 달러의 의료비가 발생합니다.
경쟁 환경
항비만 약물 시장의 주요 글로벌 업체로는 Eli Lilly and Company, Bayer AG, Bristol-Myers Squibb, Currax Pharmaceuticals LLC, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co. Inc., Norgine BV, Novo Nordisk AS, Pfizer Inc. 등이 있습니다.
COVID-19 영향 분석
러시아-우크라이나 분쟁 분석
러시아-우크라이나 분쟁은 주요 시장 참여 업체가 부족한 지역이라는 점에서 글로벌 항비만 약물 시장에 중간 정도의 영향을 미친 것으로 추정됩니다. 안보 문제, 이동 제한, 공급망 차질, 대규모 인구 이동 등으로 인해 의료 서비스 접근성이 크게 영향을 받았습니다. 다시 말해, 핵심 소재의 수입 및 수출의 중요성은 예측 기간 동안 세계 항비만 약물 시장 성장에 약간의 영향을 미칠 것으로 예상됩니다.
작용 기전별
• 말초 작용 약물
• 중추 작용 약물
약물 종류별
• 전문의약품
• 일반의약품
투여 경로별
• 경구
• 정맥/피하 주사
유통 채널별
• 병원 약국
• 소매 약국
• 온라인 약국
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽 국가
• 남미
o 브라질
o 아르헨티나
o 기타 남미 국가
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양 국가
• 중동 및 아프리카
주요 개발 사항
• 2022년 10월, 제약 회사인 일라이 릴리는 비만 또는 과체중 성인 치료를 위한 티르제파티드 연구에 대해 미국 식품의약국(FDA)의 신속 심사 지정을 받았습니다. • 체중 관련 동반 질환.

• 2022년 1월, 노보 노르디스크(Novo Nordisk AS)는 스타트업 파우나 바이오(Fauna Bio)와 파트너십을 맺고 비만 치료를 위한 독창적인 치료 전략 개발을 위해 동면하는 동물의 신진대사를 조절하는 분자와 경로를 연구하기 시작했습니다.

보고서 구매 이유:

• 작용 기전, 약물 유형, 투여 경로, 유통 채널 및 지역별 글로벌 항비만 약물 시장 세분화를 시각화하고 주요 상업적 자산과 주요 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 상업적 기회를 식별합니다.

• 모든 세그먼트를 포함한 다양한 항비만 약물 시장 수준 데이터가 담긴 엑셀 데이터 시트.

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 엑셀 파일.

글로벌 항비만 약물 시장 보고서는 약 53개의 표, 54개의 그림, 195페이지 분량입니다.

2023년 목표 고객층
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
Global Anti-Obesity Drugs Market reached US$ 2.5 billion in 2022 and is expected to reach US$ 43.7 billion by 2030 growing with a CAGR of 45.5% during the forecast period 2023-2030.
Obesity is a health disorder with surplus body fat gathered to an magnitude that it may generate a harmful consequence on health. It is typically comprehended as owning a body mass index (BMI) of 30 or above. It is distinctively identified as the biggest and rapid-growing general health concern in developed and developing nations. Anti-obesity drugs are pharmaceuticals prescribed to aid individuals who are obese. These medications function by subduing hunger, boosting metabolism, or precluding the absorption of fat from food.
The market is driven by the growing obese population, increasing awareness and product introductions into the market. The demand is again pushed by reasearch activities for new drug developments, and market developments including mergers, expansions, acquisitions and collaborations among market players.
Market Dynamics
The Growing Obese Population Drive the Growth of the Anti-obesity Drugs Market
The growing obese population is expected to boost the global anti-obesity drugs market during the forecast period. For instance, according to the World Obesity Atlas 2022, issued by the World Obesity Federation, over 1 billion individuals globally, including one out of five females and one out of seven males, were expected to be living with obesity by 2030.
Moreover, in March 2022, the WHO issued an article remarking that over 1 billion individuals are overweight globally, of which 650 million are adults, 340 million adolescents, and 39 million children. Likewise, WHO assessed that by 2025, roughly 167 million individuals would be less fit due to being overweight or obese.
Again, in March of 2023, the World Obesity Federation (WOF) published a report remarking that by 2035 more than 4 billion individuals accounting for half the world’s population is expected to be obese. Further, the World Obesity Atlas 2023, publicized by World Obesity Federation, indicates that the multinational economic effect of overweight and obesity is expected to attain $4.32 trillion perennial by 2035 if precluding and therapy standards do not enhance.
The Increasing Research Activities for Anti-obesity Drugs are Expected to Present the Global Anti-obesity Drugs Market With Growth Opportunities
Increasing research activities for anti-obesity drugs are expected to present the global anti-obesity drugs market with prospective growth opportunities in the forthcoming years. For instance, in June 2022, Innovent Biologics (Suzhou) Co. Ltd., a clinical-stage biopharmaceutical company engaged in the development of anti-obesity medication, reported its topline outcomes from its Phase II clinical trial (NCT04904913) of IBI362, a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist in China for obesity treatment.
The High Drug Cost is Estimated to Hamper the Global Anti-obesity Drugs Market During the Forecast Period
The high cost of anti-obesity drugs is estimated to hamper the global anti-obesity drug market growth in the forecast period. For instance, a four-week course of Wegovy has an index cost of $1,349 per month, although individuals with insurance that cover the drug disburse less. Provided that individuals are required to remain on the medications for life to assure they do not put weight back on.
For more details on this report - Request for Sample
Segment Analysis
The global anti-obesity drugs market is segmented based on mechanism of action, drug type, route of administration, distribution channel, and region.
The Prescription Drugs Drug Type is Estimated to Dominate the Global Anti-obesity Drugs Market
The prescription drugs drug type is expected to hold around 57.8% of the global market share owing to increased product authorization from distinct regulatory authorities. For instance, in November 2021, Novo Nordisk reported that the European regulatory authority, Committee for Medicinal Products for Human Use (CHMP), embraced a favorable view and advised the commercialization license for Wegovy for chronic weight management in adults with obesity.
Moreover, in June 2022, the U.S. Food and Drug Administration approved Qsymia as an added indication for the planning of constant weight in pediatric patients 12 years old and older who are overweight, as specified by a body mass index (BMI) of 95th percentile or more elevated when standardized for age and sex. Augmenting a low-calorie diet and a more significant workout with Qsymia is suggested.
Geographical Penetration
North America is Estimated to hold Approximately 38.3% of the Market Share by 2030, Owing to Growing Obese Population in this Region
Owing to the growing obese population in the North American region, it is estimated to dominate the global market holding around 38.3% of the market by 2030. For instance, according to the Trust for America’s Health’s (TFAH) 19th annual report on the country’s obesity, State of Obesity 2022- Better Policies for a Healthier America encountered that four out of 10 American adults are obese, and obesity rates persist to ascend nationwide.
Moreover, according to the High Obesity Program (HOP 2023) supported by the CDC, a flawed diet and lower grades of physical exercise impact general fitness and are substantial threats leading to obesity and chronic conditions. Obesity in the United States impacts 100.1 million (41.9%) grown-ups and 14.7 million (19.7%) youngsters and makes up for roughly $147 billion in annual healthcare expenditures.
Competitive Landscape
The major global players in the anti-obesity drugs market include Eli Lilly and Company, Bayer AG, Bristol-Myers Squibb, Currax Pharmaceuticals LLC, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co. Inc., Norgine BV, Novo Nordisk AS, and Pfizer Inc., among others.
COVID-19 Impact Analysis
Russia-Ukraine Conflict Analysis
The Russia-Ukraine conflict is assumed to have had a moderate impact on the global anti-obesity drugs market, as this region lacks primary market players. Access to health care is majorly affected because of security considerations, limited mobility, damaged supply chains, and mass population eviction. Again, the import and export of fundamental materials' significance is expected to slightly impact the global anti-obesity drugs market growth in the forecast period.
By Mechanism of Action
• Peripherally Acting Drugs
• Centrally Acting Drugs
By Drug Type
• Prescription Drugs
• OTC Drugs
By Route of Administration
• Oral
• Intravenous/Subcutaneous
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In October 2022, Eli Lilly and Company, a pharmaceutical corporation, obtained the U.S. Food and Drug Administration (FDA) Fast Track designation for the investigation of tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities.
• In January 2022, Novo Nordisk AS formed a partnership with the start-up Fauna Bio to investigate the molecules and pathways that regulate metabolism in hibernating creatures in demand to discover unique therapeutic strategies for obesity.
Why Purchase the Report?
• To visualize the global anti-obesity drugs market segmentation based on mechanism of action, drug type, route of administration, distribution channel and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous anti-obesity drugs market-level data points with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available in excel consisting of key products of all the major players.
The global anti-obesity drugs market report would provide approximately 53 tables, 54 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Mechanism of Action
3.2. Snippet by Drug Type
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Growing Obese Population
4.1.1.2. Market Developments
4.1.2. Restraints
4.1.2.1. High Drug Cost
4.1.3. Opportunity
4.1.3.1. Increasing Research
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. By Mechanism of Action
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mechanism of Action
7.1.2. Market Attractiveness Index, By Mechanism of Action
7.2. Peripherally Acting Drugs*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Centrally Acting Drugs
8. By Drug Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.1.2. Market Attractiveness Index, By Drug Type
8.2. Prescription Drugs*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. OTC Drugs
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Intravenous/Subcutaneous
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacies
10.4. Online Pharmacies
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mechanism of Action
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. The U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mechanism of Action
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. U.K.
11.3.7.3. France
11.3.7.4. Spain
11.3.7.5. Italy
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mechanism of Action
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mechanism of Action
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
Australia
11.5.7.4. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mechanism of Action
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Eli Lilly and Company*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Bayer AG
13.3. Bristol-Myers Squibb
13.4. Currax Pharmaceuticals LLC
13.5. F. Hoffmann-La Roche AG
13.6. GlaxoSmithKline PLC
13.7. Merck & Co. Inc.
13.8. Norgine BV
13.9. Novo Nordisk AS
13.10. Pfizer Inc.
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Product
14.2. Contact Us

언급된 주요 기업들

Eli Lilly and Company, 4.	Key Developments, Bayer AG, Bristol-Myers Squibb, Currax Pharmaceuticals LLC, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co. Inc., Norgine BV, Novo Nordisk AS, Pfizer Inc.

표 목록 (Tables)

List of Tables Table 1 Global Anti-obesity Drugs Market Value, By Mechanism of Action, 2022, 2026 & 2030 (US$ Billion)

Table 2 Global Anti-obesity Drugs Market Value, By Drug Type, 2022, 2026 & 2030 (US$ Billion)

Table 3 Global Anti-obesity Drugs Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Billion)

Table 4 Global Anti-obesity Drugs Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Billion)

Table 5 Global Anti-obesity Drugs Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 6 Global Anti-obesity Drugs Market Value, By Mechanism of Action, 2022, 2026 & 2030 (US$ Billion)

Table 7 Global Anti-obesity Drugs Market Value, By Mechanism of Action, 2021-2030 (US$ Billion)

Table 8 Global Anti-obesity Drugs Market Value, By Drug Type, 2022, 2026 & 2030 (US$ Billion)

Table 9 Global Anti-obesity Drugs Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 10 Global Anti-obesity Drugs Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Billion)

Table 11 Global Anti-obesity Drugs Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 12 Global Anti-obesity Drugs Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Billion)

Table 13 Global Anti-obesity Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 14 Global Anti-obesity Drugs Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 15 Global Anti-obesity Drugs Market Value, By Region, 2021-2030 (US$ Billion)

Table 16 North America Anti-obesity Drugs Market Value, By Mechanism of Action, 2021-2030 (US$ Billion)

Table 17 North America Anti-obesity Drugs Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 18 North America Anti-obesity Drugs Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 19 North America Anti-obesity Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 20 North America Anti-obesity Drugs Market Value, By Country, 2021-2030 (US$ Billion)

Table 21 South America Anti-obesity Drugs Market Value, By Mechanism of Action, 2021-2030 (US$ Billion)

Table 22 South America Anti-obesity Drugs Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 23 South America Anti-obesity Drugs Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 24 South America Anti-obesity Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 25 South America Anti-obesity Drugs Market Value, By Country, 2021-2030 (US$ Billion)

Table 26 Europe Anti-obesity Drugs Market Value, By Mechanism of Action, 2021-2030 (US$ Billion)

Table 27 Europe Anti-obesity Drugs Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 28 Europe Anti-obesity Drugs Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 29 Europe Anti-obesity Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 30 Europe Anti-obesity Drugs Market Value, By Country, 2021-2030 (US$ Billion)

Table 31 Asia-Pacific Anti-obesity Drugs Market Value, By Mechanism of Action, 2021-2030 (US$ Billion)

Table 32 Asia-Pacific Anti-obesity Drugs Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 33 Asia-Pacific Anti-obesity Drugs Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 34 Asia-Pacific Anti-obesity Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 35 Asia-Pacific Anti-obesity Drugs Market Value, By Country, 2021-2030 (US$ Billion)

Table 36 Middle East & Africa Anti-obesity Drugs Market Value, By Mechanism of Action, 2021-2030 (US$ Billion)

Table 37 Middle East & Africa Anti-obesity Drugs Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 38 Middle East & Africa Anti-obesity Drugs Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 39 Middle East & Africa Anti-obesity Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 40 Eli Lilly and Company: Overview

Table 41 Eli Lilly and Company: Product Portfolio

Table 42 Eli Lilly and Company: Key Developments

Table 43 Bayer AG: Overview

Table 44 Bayer AG: Product Portfolio

Table 45 Bayer AG: Key Developments

Table 46 Bristol-Myers Squibb: Overview

Table 47 Bristol-Myers Squibb: Product Portfolio

Table 48 Bristol-Myers Squibb: Key Developments

Table 49 Currax Pharmaceuticals LLC: Overview

Table 50 Currax Pharmaceuticals LLC: Product Portfolio

Table 51 Currax Pharmaceuticals LLC: Key Developments

Table 52 F. Hoffmann-La Roche AG: Overview

Table 53 F. Hoffmann-La Roche AG: Product Portfolio

Table 54 F. Hoffmann-La Roche AG: Key Developments

Table 55 GlaxoSmithKline PLC: Overview

Table 56 GlaxoSmithKline PLC: Product Portfolio

Table 57 GlaxoSmithKline PLC: Key Developments

Table 58 Merck & Co. Inc.: Overview

Table 59 Merck & Co. Inc.: Product Portfolio

Table 60 Merck & Co. Inc.: Key Developments

Table 61 Norgine BV: Overview

Table 62 Norgine BV: Product Portfolio

Table 63 Norgine BV: Key Developments

Table 64 Novo Nordisk AS: Overview

Table 65 Novo Nordisk AS: Product Portfolio

Table 66 Novo Nordisk AS: Key Developments

Table 67 Pfizer Inc.: Overview

Table 68 Pfizer Inc.: Product Portfolio

Table 69 Pfizer Inc.: Key Developments

그림 목록 (Figures)

List of Figures Figure 1 Global Anti-obesity Drugs Market Value, 2021-2030 (US$ Billion)

Figure 2 Global Anti-obesity Drugs Market Share, By Mechanism of Action, 2022 & 2030 (%)

Figure 3 Global Anti-obesity Drugs Market Share, By Drug Type, 2022 & 2030 (%)

Figure 4 Global Anti-obesity Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 5 Global Anti-obesity Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 6 Global Anti-obesity Drugs Market Share, By Region, 2022 & 2030 (%)

Figure 7 Global Anti-obesity Drugs Market Y-o-Y Growth, By Mechanism of Action, 2022-2030 (%)

Figure 8 Peripherally Acting Drugs Anti-Obesity Drugs Market Value, 2021-2030 (US$ Billion)

Figure 9 Centrally Acting Drugs Anti-Obesity Drugs Market Value, 2021-2030 (US$ Billion)

Figure 10 Global Anti-obesity Drugs Market Y-o-Y Growth, By Drug Type, 2022-2030 (%)

Figure 11 Prescription Drugs Drug Type in Global Anti-obesity Drugs Market Value, 2021-2030 (US$ Billion)

Figure 12 OTC Drugs Drug Type in Global Anti-obesity Drugs Market Value, 2021-2030 (US$ Billion)

Figure 13 Global Anti-obesity Drugs Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 14 Oral Route of Administration in Global Anti-obesity Drugs Market Value, 2021-2030 (US$ Billion)

Figure 15 Intravenous/Subcutaneous Route of Administration in Global Anti-obesity Drugs Market Value, 2021-2030 (US$ Billion)

Figure 16 Global Anti-obesity Drugs Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 17 Hospital Pharmacies Distribution Channel in Global Anti-obesity Drugs Market Value, 2021-2030 (US$ Billion)

Figure 18 Retail Pharmacies Distribution Channel in Global Anti-obesity Drugs Market Value, 2021-2030 (US$ Billion)

Figure 19 Online Pharmacies Distribution Channel in Global Anti-obesity Drugs Market Value, 2021-2030 (US$ Billion)

Figure 20 Global Anti-obesity Drugs Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 21 North America Anti-obesity Drugs Market Value, 2021-2030 (US$ Billion)

Figure 22 Asia-Pacific Anti-obesity Drugs Market Value, 2021-2030 (US$ Billion)

Figure 23 Europe Anti-obesity Drugs Market Value, 2021-2030 (US$ Billion)

Figure 24 South America Anti-obesity Drugs Market Value, 2021-2030 (US$ Billion)

Figure 25 Middle East and Africa Anti-obesity Drugs Market Value, 2021-2030 (US$ Billion)

Figure 26 North America Anti-obesity Drugs Market Value, 2021-2030 (US$ Billion)

Figure 27 North America Anti-obesity Drugs Market Share, By Mechanism of Action, 2022 & 2030 (%)

Figure 28 North America Anti-obesity Drugs Market Share, By Drug Type, 2022 & 2030 (%)

Figure 29 North America Anti-obesity Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 30 North America Anti-obesity Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 31 North America Anti-obesity Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 32 South America Anti-obesity Drugs Market Value, 2021-2030 (US$ Billion)

Figure 33 South America Anti-obesity Drugs Market Share, By Mechanism of Action, 2022 & 2030 (%)

Figure 34 South America Anti-obesity Drugs Market Share, By Drug Type, 2022 & 2030 (%)

Figure 35 South America Anti-obesity Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 36 South America Anti-obesity Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 37 South America Anti-obesity Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 38 Europe Anti-obesity Drugs Market Value, 2021-2030 (US$ Billion)

Figure 39 Europe Anti-obesity Drugs Market Share, By Mechanism of Action, 2022 & 2030 (%)

Figure 40 Europe Anti-obesity Drugs Market Share, By Drug Type, 2022 & 2030 (%)

Figure 41 Europe Anti-obesity Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 42 Europe Anti-obesity Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 43 Europe Anti-obesity Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 44 Asia-Pacific Anti-obesity Drugs Market Value, 2021-2030 (US$ Billion)

Figure 45 Asia-Pacific Anti-obesity Drugs Market Share, By Mechanism of Action, 2022 & 2030 (%)

Figure 46 Asia-Pacific Anti-obesity Drugs Market Share, By Drug Type, 2022 & 2030 (%)

Figure 47 Asia-Pacific Anti-obesity Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 48 Asia-Pacific Anti-obesity Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 49 Asia-Pacific Anti-obesity Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 50 Middle East & Africa Anti-obesity Drugs Market Value, 2021-2030 (US$ Billion)

Figure 51 Middle East & Africa Anti-obesity Drugs Market Share, By Mechanism of Action, 2022 & 2030 (%)

Figure 52 Middle East & Africa Anti-obesity Drugs Market Share, By Drug Type, 2022 & 2030 (%)

Figure 53 Middle East & Africa Anti-obesity Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 54 Middle East & Africa Anti-obesity Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 55 Eli Lilly and Company: Financials

Figure 56 Bayer AG: Financials

Figure 57 Bristol-Myers Squibb: Financials

Figure 58 Currax Pharmaceuticals LLC: Financials

Figure 59 F. Hoffmann-La Roche AG: Financials

Figure 60 GlaxoSmithKline PLC: Financials

Figure 61 Merck & Co. Inc.: Financials

Figure 62 Norgine BV: Financials

Figure 63 Novo Nordisk AS: Financials

Figure 64 Pfizer Inc.: Financials

세계 비만 치료제 시장 – 2023-2030

Global Anti-Obesity Drugs Market - 2023-2030